Hairy Cell Leukemia

---

Overview

Hairy Cell Leukemia (HCL) is a rare, slow-growing cancer of the blood and bone marrow. It is a type of lymphoid leukemia, which means it affects lymphocytes, a kind of white blood cell. The disease is named for the appearance of the cancerous cells, which have fine, hair-like projections on their surface when viewed under a microscope.

Symptoms

The symptoms of HCL can vary, but common ones include:

• Fatigue: Persistent tiredness or weakness.
• Recurrent Infections: Due to low levels of healthy white blood cells.
• Easy Bruising or Bleeding: Often due to low platelet counts.
• Swollen Lymph Nodes: Enlargement of lymph nodes, although less common in HCL.
• Fever: Often unexplained and persistent.
• Night Sweats: Excessive sweating during sleep.
• Abdominal Discomfort: Due to an enlarged spleen (splenomegaly).
• Weight Loss: Unintentional loss of weight.

Standard Treatments

1. Chemotherapy:

   • Cladribine (2-CdA): Often the first-line treatment, typically given as a single continuous infusion or as daily infusions for a week. It has been used since the 1990s.
   • Pentostatin (Nipent): An alternative to cladribine, this drug is given over several weeks. It has a similar mechanism and has been used since the late 1980s.

2. Biological Therapy:

   • Interferon-alpha: Used particularly in cases where chemotherapy is not suitable. It has been used since the 1980s, but less frequently now due to the effectiveness of other treatments.

3. Targeted Therapy:

   • Rituximab: A monoclonal antibody targeting CD20 on the surface of B cells. Used in refractory cases or relapses.

4. Splenectomy:

   • Surgical removal of the spleen may be considered if the spleen is severely enlarged or causing significant symptoms.

Experimental Treatments

• BRAF Inhibitors: Given the frequent mutation of the BRAF gene in HCL patients, inhibitors like vemurafenib have been tested with promising results.
• Immunotoxins: Drugs like moxetumomab pasudotox, which combine an antibody with a toxin to target and kill cancer cells, are undergoing trials.

Side Effects of Treatments

• Chemotherapy: Common side effects include nausea, vomiting, increased risk of infections, fatigue, and low blood cell counts.
• Biological Therapy: Interferon-alpha can cause flu-like symptoms, depression, and fatigue.
• Targeted Therapy: Rituximab can cause infusion reactions, infections, and rarely, cardiac issues.
• BRAF Inhibitors: Skin reactions, joint pain, and increased risk of other types of skin cancer.
• Immunotoxins: Potential for capillary leak syndrome, liver enzyme abnormalities, and infusion-related reactions.

Modern Advances

• Cladribine and Pentostatin: These treatments have been standard since the late 20th century, with ongoing refinements in administration and combination therapies.
• Rituximab and BRAF Inhibitors: These represent more recent advances, with significant studies published in the 2000s and 2010s.
• Immunotoxins: Still largely in the experimental stage, with clinical trials ongoing into the early 2020s.

Hairy Cell Leukemia remains a well-researched area with ongoing developments in treatment options, providing a good prognosis for many patients with the application of these therapies.